December 6, 2022-December 8, 2022 The Future of Health Summit Partnering for Patients, a Forum of the Future of Health Summit Washington, DC. December 6-8, 2022 “Creating New Markets for App
December 1, 2022 C-Path and Ultragenyx Announce Data Sharing Agreement to Support Rare Disease Treatment and Novel Therapies TUCSON, Ariz., Dec. 1, 2022 — Critical Path Institute (C-Path) and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmac
eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Implementing Numeric Rating and Visual Analog Scales in an eCOA Soluti
April 25, 2023 Approaches to the Assessment of Clinical Benefit of Treatments for Conditions That Have Heterogeneous Symptoms and Impacts Evaluating the clinical benefit of interventions aimed at treating conditions with heterogeneous symptom....
February 20, 2023 3rd PSTC Japan Safety Biomarker Workshop (presentations available) 2023 Presentations PMDA’s Perspective on the Evaluation of Novel Biomarkers (Hisanao Izumi, PhD) Biomolecular Needling System fo
December 14, 2022 View Now | Shared Stewardship in Collaborative Curation of Rare Disease Datasets Patient data is a key asset in understanding the progression of rare diseases and may it be provided in a variety of forms from a
November 16, 2022 Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital heath technologies
C-Path and Cerveau Technologies, Inc. Announce Data Sharing Collaboration to Accelerate Drug Development for Alzheimer’s Disease and Related Dementias TUCSON, Ariz., November 15, 2022 — The Critical Path for Alzheimer’s Disease (CPAD) at the Critical Path Institute (C-Path) an
November 15, 2022-November 17, 2022 Selecting Outcomes That Are Truly Meaningful to Patients Panel discussion at the National Organization of Rare Disorders (NORD) Breakthrough Summit in Washington, DC, held October 15 –